Off-label use of valves meant for treating aortic stenosis comes with worse outcomes. US operators await dedicated devices.

Remote monitoring and other innovative solutions are needed to get a handle on the more than 80% of patients who experience ...

NEW YORK, NY—A new mitral valve prosthesis—using a polymer designed to minimize the need for long-term anticoagulation—has ...

Following earlier work on erythritol, these latest findings boost concerns about not-so-sweet effects of sugar alcohols.

Five of the six senior officers for the Royal College of Physicians signed a letter asking Sarah Clarke, a cardiologist, to ...

NEW YORK, NY—Midterm results out to 3 years show that transcatheter aortic valve-in-valve (ViV) replacement for a failed ...

In patients with heart failure with reduced ejection fraction (HFrEF) who have an implantable cardioverter-defibrillator (ICD ...

Many medical professional liability (MPL) claims following noninvasive stress testing might be avoided through careful review ...

While muscle mass drops with any kind of weight loss, experts argue that the benefits outweigh the risks in those who need it ...

NEW YORK, NY—The vast majority of symptomatic patients with moderate mitral regurgitation (MR) treated with transcatheter ...

Proving physical changes to the right heart emphasizes “that TR patients need to be treated,” Dee Dee Wang says.

Michael J. Reardon and C. Michael Gibson discuss the trial's 4-year results in low-surgical-risk patients with severe aortic stenosis randomized to self-expanding TAVI or SAVR.